Hypothesis paper proposes tirzepatide for refractory endometriosis without human data
A hypothesis paper suggests tirzepatide might help endometriosis that has not responded to treatment, but it contains no human data and no evidence of benefit.
A hypothesis paper published June 24, 2026, proposes that tirzepatide might help people whose endometriosis has not responded to existing treatment, while stating that no direct experimental or clinical evidence supports the idea [1]. The article appeared in the International Journal of Molecular Sciences, volume 27, issue 13, article 5678 [1].
The journal labels the paper a Hypothesis, not a study [1]. Its authors describe a concept they call "peritoneal incretin deficiency" and propose tirzepatide — the molecule in the drugs sold as Mounjaro and Zepbound — as a possible add-on, or "multi-axis adjuvant," for treatment-refractory endometriosis [1]. The proposed mechanism covers four areas: metabolic reprogramming, peritoneal immune dysfunction, inflammatory-fibrotic remodeling, and nociceptive sensitization, which refers to changes in how pain signals are processed [1].
The authors are based at Brazilian institutions: the Brazilian Society for Research and Teaching in Medicine (SOBRAPEM), the Department of Gynecology at the Federal University of São Paulo (EPM-UNIFESP), and the Brazilian Society of Personalized Medicine (SBMP) [1]. The journal lists the paper's timeline as received May 16, 2026; revised June 13, 2026; accepted June 19, 2026; and published June 24, 2026 [1].
The paper's limitations are stated by its own authors. They write that the peritoneal incretin deficiency concept rests on a single, non-replicated case-control study, that the mechanistic chain relies on indirect evidence from other diseases, and that direct experimental or clinical validation is absent [1]. No human trial of tirzepatide in endometriosis is reported [1].
What is not established: the paper reports no patient outcomes, no dose, no safety data in people with endometriosis, and no laboratory measurements from peritoneal tissue in this group [1]. It also does not describe any regulatory filing or clinical trial program for this use [1].
Why it matters for patients
People whose endometriosis has resisted standard treatment often look for new options, and a paper proposing a new use for a widely known drug can spread online in a form that reads like proof of benefit. What this article offers is a proposed mechanism and a research idea, not a result [1]. It does not show that tirzepatide reduces endometriosis pain, lesions, or fibrosis in people, and the authors state that the validation needed to demonstrate that has not been done [1].
The paper also does not address whether tirzepatide would be safe or appropriate alongside standard endometriosis treatments, and it provides no information on interactions, side effects, or dosing in this population [1]. The gap between a mechanism drawn partly from other diseases and an effect in patients is the central caveat the authors themselves flag [1].
What happens next
The paper was published June 24, 2026 [1]. Whether the authors or other research groups plan laboratory work or a clinical trial to test the hypothesis has not been reported [1]. No study start dates, enrollment targets, or results have been disclosed [1]. As of publication, the human evidence needed to evaluate the idea does not yet exist [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.